Synaptogenix Inc (SNPX)

[runncoach]

AVXL has plenty of cash. They undergo continual dilution to make sure they have that cash and no one can blame them. And although they are decades behind original projections on every indication that hasn't disappeared from their pipeline, the fact is they have undergone clinical trials in 3 indications. Their smartest move was to advance Rett while dragging out other indications much more likely to fail. Unfortunately they delayed those Rett trials to the point where Acadia will beat them to market with a drug VERY similar to bryostatin (and that's the most important point for investors here and a fact that rarely gets enough attention) in that it's a growth factor modulator. Either way they could possibly gain Rett approval within 18 months and potential drug sales within 24 months. Big ifs of course which is why they have been trading in the single digits most of the year but at least there is some clarity (if one does their own DD as to realistic timelines and not just corporate PRs) as to potential sales pipeline and plenty of cash to start additional indications.

As with many of these small caps, buy them at the right price and at some time you'll catch a wave before results are ever reported. I get PMs all the time about competitor drugs but regardless of a drug's potential, you can dramatically increase the odds investor success if you buy low enough and hit once in a while. All is JMHO